Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Pharmaceutical Company
23.7.2024 15:00:00 EEST | Business Wire | Press release
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), today announced that it has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed contract extends through 2029 with a notable amendment that outlines a purchase commitment for two therapeutic products representing an incremental value of approximately $250 million through the end of the renewed term.
In addition, KBI, in late June, completed a successful regulatory inspection by the U.S. Food and Drug Administration (FDA) of its mammalian operation in Durham, North Carolina. This regulatory inspection enables the company’s North Carolina operations to begin providing a mammalian drug substance commercially to one of its key strategic customers. It also demonstrates KBI’s ability to act as a preferred partner for large volume commercial therapeutic manufacturing.
“As KBI continues fulfilling its commitment to our customers in helping solve their complex manufacturing challenges, this commercial contract extension allows us to demonstrate our approach as a next-generation CDMO,” said J.D. Mowery, President and CEO of KBI Biopharma. “With this agreement as well as our successful FDA regulatory inspection, we’re driving breakthroughs in biopharmaceutical development and manufacturing that help bring new therapies to market.”
He concluded, “By establishing these trusted, long-term partnerships with global pharmaceutical leaders, we’re able to positively impact the lives of patients worldwide.”
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. With each of its 500+ customer partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian and microbial programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global customers with six locations in Europe and the USA. More information is available at www.kbibiopharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723243720/en/
Contacts
KBI Biopharma, Inc. Company Inquiries
Sarah Wakefield
KBI Biopharma, Inc.
swakefield@kbibiopharma.com
KBI Biopharma, Inc. Media Inquiries
Kelly Biele
CG Life
kbiele@cglife.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mindbreeze InSpire Reduces Token Maxxing, Turning Runaway AI Costs Into Predictable Enterprise Value28.7.2026 16:03:00 EEST | Press release
Mindbreeze, a leading global provider of AI-based knowledge management solutions, today announced that Mindbreeze InSpire reduces token maxxing, the costly overconsumption of large language model (LLM) tokens that is straining enterprise AI budgets. By retrieving only the most relevant, grounded content and passing it to LLMs with precision, Mindbreeze InSpire lowers the tokens required per answer while improving accuracy, giving enterprises a path to scalable AI with predictable economics. Token maxxing has become one of the most underestimated risks in enterprise AI. As organizations connect generative AI to their data, many default to injecting large volumes of undifferentiated context into every prompt, repeatedly, across thousands of queries. Industry analysis has warned that tokens are becoming the true unit of AI cost, with usage-driven and nonlinear spending that is difficult to forecast and quick to erode margins. The problem is rarely the model. It is what the model is asked
Uptime Institute 16 th Annual 2026 Global Data Center Survey: Deployment of High Density Racks Rising Fast, Operators Face Continued Recruiting and Retention Pressures28.7.2026 16:02:00 EEST | Press release
Uptime Institute today released the findings of its 16th Annual Global Data Center Survey, the most comprehensive study of the digital infrastructure sector. The 2026 results reveal an industry navigating workforce constraints, escalating outage expenses, even as rising costs remain the top concern for management teams. Financial Pressure and Resource Constraints Intensify: While high costs continue to be a primary concern for data center leaders, the 2026 survey also highlights escalating concerns over capacity forecasting, power availability, and supply chain disruptions. Power efficiency gains remain gradual. The industry saw minor improvements in average Power Usage Effectiveness (PUE) levels this year. While newer facilities may boast highly efficient designs, overall global progress is slowed by legacy infrastructure. The AI and Density Reality Check: Despite market enthusiasm for Artificial Intelligence, expectations for AI in data center operations cooled slightly in 2026. Oper
Torq Unveils the SOC Brain: The AI SOC That Learns, Not Just Remembers28.7.2026 16:00:00 EEST | Press release
Torq, the established agentic security operations leader, today introduced Torq SOC Brain™, a new layer of the Torq AI SOC Platform that continuously learns from historical investigations, analyst decisions, and organization-specific security operations to create a unified, self-learning AI SOC. While most autonomous investigation systems claim to be self-learning, they are, in reality, memory systems—they simply retrieve past cases and pass them to a language model at decision time. Torq SOC Brain is fundamentally different. It reasons from precedent, adapts to how each SOC evaluates risk, and continuously refines its judgment with every completed investigation. The result is an AI SOC that grows more accurate over time—not a thin wrapper around a generic AI model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728408536/en/ Torq SOC Brain demos are available for qualified Black Hat USA 2026 attendees at the Torq booth a
AUTOBACS SEVEN Marks 10 Years of System Stability and Self-Funded Innovation with Rimini Street28.7.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that AUTOBACS SEVEN Co., Ltd. celebrates its 10-year partnership with Rimini Street, marking a decade of stable core operations and reinvestment in innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728266493/en/ AUTOBACS SEVEN Marks 10 Years of System Stability and Self-Funded Innovation with Rimini Street Since switching to Rimini Support™ for SAP ECC 6 in 2016, AUTOBACS SEVEN has expanded its partnership to include Oracle Database, helping the company stabilize mission-critical systems, reduce maintenance burden and free resources for innovation. “At AUTOBACS SEVEN, our leadership team meets regularly to discuss how we will grow as a company over the next five to ten years. During these conversations, we talk openly about how to be
Abnormal AI Extends its Behavioral Security Platform to Identity and AI Security28.7.2026 16:00:00 EEST | Press release
Abnormal AI, the AI-native behavior security company trusted by more than 25% of the Fortune 5001, today announced the expansion of its Behavioral Security Platform across the enterprise, introducing three new products: Identity Threat Protection, AI Governance, and Infiltration Prevention. Together, the launch extends the behavioral AI that already secures over 4,500 customers1 to the identities, AI systems and onboarding pipeline that attackers increasingly exploit. Additionally, customers can now activate products from the AI App Store, a new interface to turn on Abnormal products in a single click. For nearly a decade, Abnormal has protected organizations by understanding behavior, learning what normal looks like for every identity and detecting the deviations that signal anomalous activity or an attack. That behavioral foundation spanning email, sign-in, and communication signals, now extends across the enterprise identity attack surface. “Abnormal envisioned a future where behavi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom